Markets
Stocks
Funds
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Recent Quotes
My Watchlist
Indicators
Akorn Inc (NQ: AKRX)
3.840 USD  UNCHANGED
Streaming Delayed Price  /  Updated: 9:43 AM EDT, Jul 22, 2019  /  Add to My Watchlist      
View: Quote News Research
Price and Volume
Detailed Quote
Chart for (: )
 
Intraday
1 Week
1 Month
3 Month
1 Year
  
Compare to:
Volume 41,549
Open 3.860
Bid (Size) 3.840 (5)
Ask (Size) 3.850 (1)
Prev. Close 3.840
Today's Range 3.820 - 3.920
52wk Range 2.640 - 19.65
Shares Outstanding 125,258,615
Dividend Yield N/A
Performance
YTD
+10.34%
+10.34%
1 Month
-19.67%
-19.67%
3 Month
+28.43%
+28.43%
6 Month
+4.63%
+4.63%
1 Year
-77.76%
-77.76%
Top News
More News
Akorn to Report Second Quarter 2019 Financial Results and Host Conference Call
Akorn, Inc. (Nasdaq: AKRX), a leading specialty generic pharmaceutical company, today announced that it plans to issue a press release before market open on Thursday, August 1, 2019 outlining its... Read More
from GlobeNewswire News Releases
Akorn Announces Launch of Loteprednol Etabonate Ophthalmic Suspension, 0.5%
Akorn, Inc. (Nasdaq: AKRX), a leading specialty generic pharmaceutical company, today announced that it has launched its first-to-market generic of Loteprednol Etabonate Ophthalmic Suspension, 0.5%. Read More
from GlobeNewswire News Releases
More News
Read More
Akorn Receives FDA Warning Letter
from GlobeNewswire News Releases
Akorn to Present at the Jefferies 2019 Global Healthcare Conference
from GlobeNewswire News Releases
Akorn Receives FDA Approval for Azelastine Hydrochloride Nasal Spray, 0.1%
from GlobeNewswire News Releases
Analysts Anticipate 22% Gains Ahead For IHE
category ETFs
from ETF Channel
Akorn to Present at the RBC Capital Markets Healthcare Conference
from GlobeNewswire News Releases
Akorn Inc Has Returned 26.4% Since SmarTrend Recommendation (AKRX)
from Comtex SmarTrend® News Briefs
UPDATE 3-Akorn gets FDA warning letter for another manufacturing plant
category companyNews
from Reuters: Company News
Akorn Receives FDA Warning Letter, Says It's Committed To Resolving Issues
category FDA , Benzinga , AKRX , and 4 more.
from Benzinga
UPDATE 2-Akorn gets another FDA warning letter, shares slide
category companyNews
from Reuters: Company News
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Six Financial & Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.